Opposing effects of β blockers and angiotensin-converting enzyme inhibitors on development of new-onset diabetes mellitus in patients with stable coronary artery disease.

[1]  C. Dollery,et al.  Glucose Tolerance During Antihypertensive Therapy in Patients with Diabetes Mellitus , 1985, Hypertension.

[2]  L. Groop,et al.  Glucose and free fatty acid metabolism in non-insulin-dependent diabetes mellitus. Evidence for multiple sites of insulin resistance. , 1989, The Journal of clinical investigation.

[3]  B. Saltin,et al.  The metabolic and circulatory response to beta-blockade in hypertensive men is correlated to muscle capillary density. , 1992, Blood pressure.

[4]  L. Lind,et al.  Metabolic effects of anti-hypertensive treatment with nifedipine or furosemide: a double-blind, cross-over study. , 1995, Journal of human hypertension.

[5]  R. Marfella,et al.  Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension. A randomized, controlled trial. , 1997, Annals of internal medicine.

[6]  R. Marfella,et al.  Metabolic and Cardiovascular Effects of Carvedilol and Atenolol in Non-Insulin-Dependent Diabetes Mellitus and Hypertension , 1997, Annals of Internal Medicine.

[7]  M. Elam,et al.  The effect of metoprolol treatment on insulin sensitivity and diurnal plasma hormone levels in hypertensive subjects , 1997, European journal of clinical investigation.

[8]  S. Haffner.  The prediabetic problem: development of non-insulin-dependent diabetes mellitus and related abnormalities. , 1997, Journal of diabetes and its complications.

[9]  R. Fogari,et al.  Comparative effects of lisinopril and losartan on insulin sensitivity in the treatment of non diabetic hypertensive patients. , 1998, British journal of clinical pharmacology.

[10]  M. Pfeffer,et al.  Prevention of events with angiotensin-converting enzyme inhibition (the PEACE study design). Prevention of Events with Angiotensin-Converting Enzyme Inhibition. , 1998, The American journal of cardiology.

[11]  L. Niskanen,et al.  Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial , 1999, The Lancet.

[12]  S. Yusuf,et al.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. , 2000 .

[13]  F. Nieto,et al.  Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus , 2000 .

[14]  K. Nonogaki,et al.  New insights into sympathetic regulation of glucose and fat metabolism , 2000, Diabetologia.

[15]  S. Yusuf,et al.  Ramipril and the development of diabetes. , 2001, JAMA.

[16]  M. Nieminen,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[17]  S. Jacob,et al.  Angiotensin converting enzyme inhibitors and modulation of skeletal muscle insulin resistance , 2003, Diabetes, obesity & metabolism.

[18]  A. Ducharme,et al.  Enalapril Decreases the Incidence of Atrial Fibrillation in Patients With Left Ventricular Dysfunction Insight From the Studies Of Left Ventricular Dysfunction (SOLVD) Trials , 2003, Circulation.

[19]  Merlin C. Thomas,et al.  Improved islet morphology after blockade of the renin- angiotensin system in the ZDF rat. , 2004, Diabetes.

[20]  M. Shichiri,et al.  Effect on insulin sensitivity of angiotensin converting enzyme inhibitors with or without a sulphydryl group: Bradykinin may improve insulin resistance in dogs and humans , 1994, Diabetologia.

[21]  P. Raskin,et al.  Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. , 2004, JAMA.

[22]  M. Pfeffer,et al.  Angiotensin-converting-enzyme inhibition in stable coronary artery disease. , 2004, The New England journal of medicine.

[23]  R. Collins,et al.  Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled tri , 2005, The Lancet.

[24]  M. Pfeffer,et al.  Effects of Candesartan on the Development of a New Diagnosis of Diabetes Mellitus in Patients With Heart Failure , 2005, Circulation.

[25]  B. Davis,et al.  Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). , 2006, Archives of internal medicine.

[26]  Jackson T. Wright,et al.  Differing effects of antihypertensive drugs on the incidence of diabetes mellitus among patients with hypertensive kidney disease. , 2006, Archives of internal medicine.

[27]  Janet B McGill,et al.  Body weight changes with beta-blocker use: results from GEMINI. , 2007, The American journal of medicine.

[28]  P. Poole‐Wilson,et al.  Effects of metoprolol and carvedilol on pre-existing and new onset diabetes in patients with chronic heart failure: data from the Carvedilol Or Metoprolol European Trial (COMET) , 2007, Heart.

[29]  Robert A. Phillips,et al.  Body Weight Changes with β-Blocker Use: Results from GEMINI , 2007 .

[30]  S. Bangalore,et al.  A meta-analysis of 94,492 patients with hypertension treated with beta blockers to determine the risk of new-onset diabetes mellitus. , 2007, The American journal of cardiology.

[31]  J. LeLorier,et al.  Effect of ramipril on the incidence of diabetes. , 2007, The New England journal of medicine.

[32]  William J. Elliott.  Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis , 2008 .